J1414, Injection, fidanacogene elaparvovec-dzkt, per therapeutic dose
HCPCS/CPT
Prior Authorization
No Prior Auth Required
Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
0.00
Facility
N/A
Non-Facility
N/A
Documentation Required
- Authorization limited to one Beqvez/Hemgenix treatment per lifetime and for a duration not to exceed 45 days from approval.
- Documentation requirements: weekly monitoring of ALT/AST and factor IX activity for 4 months post-Beqvez; counseling on alcohol risks; dosing per FDA labeling; no planned inpatient admission solely to administer Beqvez; authorization limited to one treatment per lifetime and max 45 days.
Key Coverage Criteria
- Beqvez is proven and medically necessary for the treatment of Hemophilia B (congenital factor IX deficiency) when all of the following criteria are met: 1) Patient is 18 years of age or older; and 2) One of the following: a) Both of the following: i) Diagnosis of severe hemophilia B; and ii) Documentation of endogenous factor IX levels less than 1% of normal factor IX (< 0.01 IU/mL) or b) All of the following: i) Diagnosis of moderately severe hemophilia B; and ii) Documentation of endogenous fa [...]
- Etranacogene dezaparvovec-drlb is consideredmedically necessaryin individuals who meetallof the following criteria:
- Diagnosis of hemophilia B;and
- Age 18 years or older;and
- Baseline factor IX level is less than 1 international unit (IU)/deciliter (dL) (or 1% endogenous factor IX);and
- No contraindications to infusion (if any of the following are present, treatment is contraindicated):Active infection;orImmunosuppressive disorder;orLiver cirrhosis;orActive hepatitis B or C;orAlanine transaminase (ALT) greater than 3 times the upper limit of normal;orBilirubin greater than 3 times the upper limit of normal;orAlkaline phosphatase greater than 3 times the upper limit of normal;orInternational normalized ratio (INR) greater than1.4.;orPrior infusion of gene therapy for hemophilia [...]
4 Active Policies
ANTHEM-MED.00135, MED.00135 Gene Therapy for Hemophilia
UHC-POL-gene-therapies-hemophilia, Gene Therapies for Hemophilia B
UMR-POL-UMR-gene-therapies-hemophilia, Gene Therapies for Hemophilia B
SUREST-POL-SUREST-gene-therapies-hemophilia, Gene Therapies for Hemophilia B
Related Codes
Have a follow-up question?
Ask Verity about documentation requirements, denial risks, or coverage in your state.